Cspc Innovation Pharmaceutical Co.,Ltd. (ASX: 300765) has announced that the resolutions from its third extraordinary shareholders' meeting of the year 2026 have been passed.
The meeting, held on July 8, successfully reviewed and approved a proposal concerning the company's engagement in foreign exchange hedging activities.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments